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Abstract
Background: Thailand is a major destination for German travellers with more than 760,000 arrivals in 2015. At the
same time, malaria is a concern in travel recommendations with regard to this destination. The World Malaria
Report of 2016 mentions only P. falciparum and P. vivax as prevalent species for Thailand, however, P. knowlesi
infections have been occasionally reported in Thailand. In German travellers, only five cases of P. knowlesi infections
have been reported to date.
Case presentation: A 45-year-old German male tourist travelled to Thailand from 25 December 2016 to 13 January
2017. On 14 January he developed fever with no other symptoms, and presented on 17 January at the Division for
Tropical Medicine and Infectious Diseases in Munich, Germany.
Malaria was diagnosed, primarily based on a single parasite in the thin smear microscopy, while commercial rapid
diagnostic testing remained negative. Only the result of a differential PCR assay revealed P. knowlesi infection.
Conclusions: P. knowlesi has to be considered in travellers returning from Thailand. Cases may present with an
extremely low parasitaemia. This is in contrast to the assumption that P. knowlesi was likely to cause high
parasitaemia due to its short replication cycle.
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Background
Despite considerable reductions in morbidity, malaria re-
mains to be a relevant public health concern for Southeast
Asia. The WHO World Malaria Report 2016 estimates
52,000 malaria infections for the year 2015 for Thailand
among a total population of 68.2 million [1]. At the same
time, the region represents an important tourist travel
destination. The total number of incoming tourists to
Thailand has increased almost fivefold in the past 20 years,
from 7 million per year in 1995 to 33 million in 2016 [2].
In 2015 more than 760,000 travellers from Germany
visited Thailand, the majority for leisure purposes [3].
Thailand is in most parts considered a low risk destination
concerning malaria infections in travellers, thus current
preventive algorithms recommend exposure prophylaxis
through use of insecticide treated bed nets and repellents
for most major tourist destinations, without a general rec-
ommendation of antimalarial chemoprophylaxis. For lon-
ger trips that include stays in rural areas, German and
Swiss guidelines, and the recent update of UK guidelines
of 2017 recommend provision of an emergency standby
medication [4, 5]. The CDC and the previous UK national
guidelines advise taking antimalarial chemoprophylaxis
for some rural areas, e.g. the forested areas bordering
Cambodia, Myanmar and Laos [6, 7]. Recommended anti-
malarials for chemoprophylaxis are atovaquone/proguanil
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or doxycycline due to concerns over possible mefloquine
resistance.
The incidence of malaria across all Plasmodium spe-
cies in travellers to Thailand from 12 European coun-
tries and the USA has been reported by Behrens et al. at
0.60 cases per 100,000 visits for the year 2008 [8]. The
species distribution for malaria infections in Thailand is
reported by the World Malaria Report 2016 at 41.8% for
P. falciparum and at 58.2% for P. vivax [1]. Plasmodium
knowlesi infections are not reported at all in some publi-
cations, including the WHO world malaria report of
2016 [1], or as rare events in others. The occurrence of
autochthonous infections in Thailand appears to be con-
centrated around the southern provinces [9–11].
P. knowlesi has been known as the “fifth malaria spe-
cies” that naturally infects humans (recently there have
been two distinct species identified in P. ovale, increas-
ing the number of human-pathogenic species to six). In
contrast to P. falciparum, P. vivax and P. ovale spp. it is
mostly a zoonotic parasite that shows a high prevalence
in macaques, in particular in Malaysia. The species P.
malariae is known as an anthropozoonotic parasite. Dif-
ferent Anopheles species have been described as poten-
tial vectors, with divergent feeding affinities towards
humans and non-human primates. First infections in
humans were reported from Malaysia in 1965, and hu-
man infections have been reported as rare events ever
since. However, in a retrospective study in Malaysia on
samples of patients that had been diagnosed with P.
malariae infections, actually 82% of infections were re-
vealed by species-specific molecular analysis as having
been caused by P. knowlesi [12] . Also problematic is the
reported lack of reliability of common rapid diagnostic
tests in detecting P. knowlesi infections [13]. P. knowlesi
poses also challenges on malaria prevention efforts, as
transmission appears to frequently occur outside homes,
rendering bed net use futile [14].
In German travellers returning from Southeast Asia, P.
knowlesi infections are analogously considered very rare
events. In the available literature, there have been five
cases reported in returning German travellers altogether,
which have all been visitors to Thailand [15–19].
This article is presenting a further case of a P. knowlesi
infection in a returning German traveller from Thailand,
and highlights the difficulties in accomplishing the cor-
rect diagnosis. In addition, possible consequences for
current travel recommendations are considered.
Case presentation
Clinical history and physical findings
The patient, a 45-year-old male Caucasian German, born
and residing in the German county of Bavaria, travelled
to Thailand for holiday purposes repeatedly over the
past years. The most recent journey started on 25
December 2016 with a flight from Munich, Germany to
Muscat, Oman, where he had a 2-h stopover, before
continuing to Bangkok, Thailand, where he arrived on
26 December. He spent the time from 26 December
2016 to 01 January 2017 in Chiang Mai in the north of
Thailand where he visited the Doi Inthanon National
Park. On 01 January he travelled to Bangkok where he
stayed until 03 January, followed by a stay in Ranong city
from 03 to 05 January. He then spent the time from 05
to 11 January on the island of Little Koh Chang in the
Andaman Sea, which is part of Ranong Province. Via the
city of Ranong he continued back to Bangkok where on
13 January he boarded a flight to Munich, Germany via
Muscat, Oman (Fig. 1).
The patient travelled together with his partner who
remained without health problems. He did not receive a
specialized pre-travel consultation and did not take any
antimalarial chemoprophylaxis, which is conforming to
current German travel recommendations for Thailand.
Regular use of repellents and of bed nets was reported.
He did not reveal a medical history indicative of previ-
ous malaria infections.
Clinical course
During the stay in Thailand the patient did not report
any remarkable symptoms except painful and inflamed
insect bites on two occasions while sleeping on the is-
land of Koh Chang. On 14 January, the day after his re-
turn to Germany, he started to feel chills and developed
fever up to 40 °C. He also developed profuse sweating,
particularly at night time. Other symptoms such as ar-
thralgias, myalgias or headaches were not present. He
did not report any gastrointestinal, urinary tract or re-
spiratory symptoms. After a brief consultation with the
family physician in the patient’s rural area of residence
in Bavaria on 16 January, he was referred to the Division
of Infectious Diseases and Tropical Medicine (DIDTM)
of the Medical Centre of the University of Munich
(LMU) for further investigation.
Upon presentation, the patient’s general condition was
only slightly reduced, temperature by tympanic measure-
ment was 38.8 °C. The physical examination did not re-
veal any other remarkable findings. On abdominal
ultrasound no pathological findings could be established,
particularly the spleen appeared normal in size and
ultrasound pattern.
Laboratory diagnostics
Laboratory analyses were conducted in-house on whole
blood and plasma samples upon attendance of the patient
at DIDTM on day 4 after onset of symptoms. Automated
full blood count was followed by visual differentiation of
thin smears. As stipulated by the malaria emergency diag-
nostics protocol of DIDTM, screening for parasites was
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initiated by microscopical examination of thin smears on
100 fields at 400-fold magnification following Diff-Quik
staining (Dade-Behring/Medion Diagnostics, Duedingen,
Switzerland). Subsequently, Giemsa stained thick smears
were examined. Furthermore, the rapid diagnostic tests
BinaxNow Malaria (Alere, Scarborough, Maine, USA) for
the detection of antigens of P. falciparum and/or P. vivax/
P. ovale spp./P. malariae, Dengue Duo (SD Bioline,
Yongin-si, Gyeonggi-do, Republic of Korea) for the detec-
tion of the non-structural protein 1 (NS1)/IgM/IgG and
the Afinion C-reactive protein (CRP) test (Alere) were
conducted. The Plasmodium genus-specific real-time PCR
FTD Malaria (Mikrogen Diagnostik, Neuried, Germany)
was carried out followed by the multiplex PCR FTD
Malaria differentiation (Mikrogen) for the detection of P.
falciparum, P. vivax, P. ovale spp. and P. malariae. In
cases of positive amplification of Plasmodium genus-
specific sequences and negative multiplex PCR FTD Mal-
aria differentiation test results, the P. knowlesi nested PCR
as first described by Imwong et al. based on a 410 base
pair fragment of the species-specific P. knowlesi 18S rRNA
gene is applied at DIDTM [20]. For immunodiagnosis an
in-house immunofluorescence test employing P. falcip-
arum and P. vivax antigens was conducted.
In addition, a full blood sample was sent to the na-
tional reference laboratory for PCR-based malaria differ-
entiation at the Bernhard-Nocht-Institute for Tropical
Medicine (BNITM), Hamburg, Germany.
Fig. 1 Map of Thailand with Itinerary. This map is based on a map by the Department of Field Support, Cartographic Section of the United
Nations [30]. The map of Thailand shows the itinerary of the presented case
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Results
As the automated blood count and the CRP rapid test
results are conducted in-house at DIDTM, these results
were available within the first half hour of presentation,
and revealed a marked thrombocytopenia of 79/nl (nor-
mal range 140–360/nl) and an elevated CRP (later quan-
tified at 10.6 mg/dl; normal range < 0,5 mg/dl). At the
same time the Dengue rapid test and the malaria rapid
diagnostic test were negative.
The thin blood smears revealed a Plasmodium infec-
tion at an extremely low parasitaemia. In the examin-
ation of 100 investigated fields at × 400 magnification
only 1 parasite was detected. Consecutively the full thin
smear slides were investigated, revealing a total of 3 par-
asites: one gametocyte and 2 trophozoites (parasite dens-
ity 0.0002%) (Fig. 2).
The aspects of the identified gametocyte and the tro-
phozoites rather resembled P. vivax. Examination of the
thick smear again revealed only 1 structure suggesting a
Plasmodium infection without allowing further differen-
tiation. With this finding, treatment was initiated with a
3-day course of atovaquone 250 mg/ proguanil 100 mg,
4 tablets daily, as recommended by the national malaria
guidelines of the Association of the Scientific Medical
Societies in Germany [21]. Due to the only mildly re-
duced general condition of the patient the decision for
outpatient management was taken. The same day the
Plasmodium genus-specific PCR tested positive but the
differential PCR revealed negative results for P. falcip-
arum, P. vivax, P. ovale and P. malariae. Both the
DIDTM and the national reference laboratory at BNITM
returned a positive PCR result for P. knowlesi.
Fever and sweats settled the evening the first dose of
atovaquone/ proguanil was given. The patient was seen
again at DIDTM on 18 and 23 January, when repeated
blood counts and smears were performed. Thrombocyte
levels went down to 75/nl on 18 January, and returned
to normal levels by 23 January. Blood smears on both
follow-up days remained negative for parasites. The ser-
ology for P. falciparum and P. vivax remained negative.
The patient improved without any signs of adverse treat-
ment effects (Table 1).
Discussion and conclusions
In the currently available literature, knowlesi malaria re-
mains a rather rare event outside Malaysia, and particu-
larly rare in travellers returning from Southeast Asia. Of
note, the World Malaria Report 2016 does not state any
P. knowlesi infection for Thailand, but only P. falcip-
arum and P. vivax infections [1]. However, recent stud-
ies are indicating endemicity for P. knowlesi also in other
Southeast Asian countries, such as Myanmar and
Indonesia [22, 23].
Based on reported incubation periods for knowlesi
malaria of about 9 to 12 days [24], it seems likely that
the infection in this patient was acquired on the island
of Little Koh Chang in the Andaman Sea, which is not
to be confused with the much larger island of Koh
Chang in the Gulf of Thailand. As macaques are the
main reservoir of P. knowlesi, further studies are needed
to assess the prevalence of the parasite in the monkey
population on this island, which is a hideaway recom-
mendation for tourists that intend to avoid the main
crowds on the Thai islands on the gulf side.
As has been described in other publications, knowlesi
malaria has to be suspected in situations where commer-
cial rapid diagnostic tests reveal negative results in sam-
ples with positive blood smears [13, 17, 18]. The
morphology of parasites in smears appears to be hetero-
geneous, and does not allow for a conclusive diagnosis
[25]. Also, parasitaemia at presentation can be very low
rendering parasite identification even more challenging,
although potential hyperparasitaemia has been reported
Fig. 2 Photographic Image of a P. knowlesi Trophozoite. The figure
shows a photographic image of a P. knowlesi trophozoite in a thin
smear specimen of the reported patient at 400 x magnification
Table 1 Timeline of Case History
Date History
25 December
2016
Flight Munich, Germany to Bangkok, Thailand
05 January 2017 Passage to Koh Chang Island
11 to 13 January
2017
Return to Munich, Germany
14 January 2017 Onset of Symptoms
17 January 2017 Presentation at DIDTM, diagnosis of plasmodium
infection, initiation of treatment
17 to 18 January
2017
Cessation of fever, clinical improvement
23 January 2017 Follow-up visit at DIDTM, normalization of
thrombocyte count
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[25]. In cases where Plasmodium-species differentiation
is hampered, it is recommended to do a differential PCR
[26]. In the case presented here, the extremely low para-
sitaemia could even have led to a negative smear result
in the first set of specimens. Only one gametocyte that
was found in 100 visual fields of the blood smears led to
the positive result of a plasmodium infection. The neces-
sity of taking repetitive blood samples in the traveller
with fever of unknown aetiology returning from malaria-
endemic areas has to be kept in mind. In addition, an in-
fection by P. knowlesi has to be suspected when the
commercially available malaria PCR assays reveal a con-
stellation of a positive genus specific sequence together
with negative results for species specific sequences, as
these usually do not comprise P. knowlesi.
As both artemisinine combination therapies [27] and
atovaquone/ proguanil [28] seem to be effective in pa-
tients not showing severe illness with both P. knowlesi
and P. falciparum infections, these should be considered
as first line presumptive treatments where inconsistent
laboratory results hamper an instant conclusive diagno-
sis. In our patient a rapid cessation of fever could be
reached with atovaquone/ proguanil within 12 h of the
first administered dose.
It is noteworthy that malaria prevention guidelines re-
garding travels to Thailand do differ between Germany,
Switzerland, the UK and the USA. Both the German and
the Swiss guidelines do not recommend antimalarial
chemoprophylaxis for any region of Thailand, but recom-
mend provision of standby medication for stays in the
border regions particularly when outside reach of health
care facilities [4, 5]. Contrary to that, the current US and
the previous UK (until 2017) guidelines do recommend
chemoprophylaxis with atovaquone/ proguanil or doxy-
cycline for stays in border regions [6, 7], such as Ranong
Province, bordering Myanmar, where our patient travelled
to. The recent update of 2017 of the UK guidelines has
now dropped the recommendation on chemoprophylaxis
[29]. Adherence to the previous UK and current US guide-
lines would most likely have prevented this course of a P.
knowlesi infection. Nevertheless, the authors are just able
to present one case in this report, whereas recommenda-
tions for malaria prevention have to be based on risk mod-
elling for geographic regions which are based on larger
datasets. However, it has to be kept in mind that Thailand
remains a favourite travel destination for German tourists,
and diagnostic and treatment algorithms for febrile
returning travellers have to take into consideration P.
knowlesi infections. Diagnosis can be challenging due to
ambiguous morphology of plasmodial parasites, very low
levels of parasitaemia and negative results in commercially
available rapid diagnostic tests. Treatment with atova-
quone/ proguanil showed to be effective with rapid clinical
improvement.
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